ACHEMA 2022, 22 – 26 August 2022 in Frankfurt, Germany
ACHEMA is the world forum and leading trade show for the chemical, pharmaceutical and food industries. It’s where new developments are unveiled and trends are discussed.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2062 entries already.
Entries by Thomas Gabrielczyk
Swedish SOBI awarded rights to market Zynlonta from ADC therapeutics
In a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US.
ECBF joins Novo Seeds and Sofinnova Partners in EUR11.5m round in Biosyntia
The European Circular Bioeconomy Fund (ECBF) expands its industrial biotechnology portfolio by joining the financing Series B of danish Biosyntia ApS. Biosyntia is a precision fermentation company focused on bio-based production for products such as vitamins and other ingredients.
Lonza invests CHF500m in Large-Scale Facility in Stein (CH)
Large CDMO Lonza to build a new large-scale, commercial drug product facility including fill and finish to support customers across the entire product life cycle in Switzerland, investment of CHF500m.
Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac
Evotec, pharma giant Boehringer Ingelheim, and IVD specialist bioMérieux have launched a €40m joint venture to fight Antimicrobial Resistance (AMR).
Urovant Sciences cashes in $75m in licence deal from Pierre Fabre
French drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences’ drug vibegron for the treatment of overactive bladder in Europe.
CureVac NV sues BioNTech for IP infringement
German mRNA vaccine developer CureVac, whose COVID-19 vaccine was not effective, on Monday sued BioNTech/Pfizer for infringement of four patents.
French Ipsen falls after Epizyme take-over announcement
Shares of French drugmaker Ipsen fell by 4.4% at Euronext Paris after the company announced to take over US cancer specialist Epizyme Inc. for $247m.
TWB announces winners in industrial biotech start-up contest
At the end of the TWB Start-up day, which was attended by more than 200 biotech professionals, two industrial biotechnology companies were awarded prizes worth €50,000.
BIONTech breaks ground for manufacturing site in Rwanda
BioNTech SE has announced it is going to ship the first containers for mRNA malaria vaccine production from this year’s end toKigall.